Qingkong SinoKing Capital
8th Floor, Science and Technology Building C, Tsinghua Science and Technology Park, Beijing, Haidian District, 100084, China
Overview
Sinoking Capital invests in private equity in business throughout China. It invests in and manages M&A funds, focusing on M&A opportunities in information technology, energy conservation and environmental protection, medical and health, cultural media, advanced manufacturing, new materials, and new energy. It makes full use of the advantages of Tsinghua's industrial resources and financial resources, and assists the investee enterprises to enhance their core competition by providing target companies with a series of value-added services including brand enhancement, management improvement, mechanism adjustment, strategic consulting, industry integration, business restructuring, and financial services ability. It has led and assisted in the completion of major mergers and acquisitions of companies such as Spreadtrum, Radicco, H3C, Wison Energy, Sander Environment, Howe Technology, and Huzhong Advertising.
- Total investments
- 4
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Exchanges
- Financial Services
- Impact Investing
- Venture Capital
Investment portfolio
- Purspec
Led · Series A · May 2024
Qingpu Technology develops, produces and manufactures high-end mass spectrometry analysis products aimed at on-site detection and scientific research, offering real-time, accurate and easy-to-use testing solutions. The company has designed multiple portable mass spectrometers and related systems, including the MS Mate in‑situ ionization source and the ΩAnalyzer for lipid double-bond localization. Its Mini β compact mass spectrometry analysis system won the 2017 BCEIA Gold Award and a 2017 scientific-instrument industry new-product award. Qingpu focuses on both product development and manufacturing of high-end spectrometry instruments for field and laboratory use. Recently the company completed a near-RMB 100 million A+ financing round, indicating an injection of capital to support its operations and growth.
- Zhiyi Pharmaceutics
Participated · Series B · Jul 2022
Zhiyi Biotech is a Guangzhou-based biopharmaceutical R&D firm focused on next-generation probiotics (NGPs) and live biotherapeutics (LBPs) alongside associated therapeutic approaches. The company develops new-drug candidates and therapeutic modalities built on its NGP/LBP platforms. It recently completed the first tranche of a C round financing, raising nearly ¥100 million RMB. Proceeds from the tranche are designated primarily for clinical development across its pipeline. In particular, the company intends to use the funds to advance its candidate SK08 into a Phase III clinical trial. The article does not provide operating metrics, past funding history, or founding year. Zhiyi Biotech is a clinical-stage LBP developer that has built a technical and industrial platform spanning strain isolation, identification, innovative LBP development, CMC and commercial production. Its lead candidate, SK08, is based on a single bacterial strain, Bacteroides fragilis, and is ahead of other LBPs in China. SK08 is expected to complete a Phase II trial in China this year for IBS-D and has an ongoing Phase Ib/II study in combination with a PD-1 inhibitor for advanced solid tumors. The company reports multiple programs preparing IND filings to both the FDA and China’s NMPA, and expects additional programs to enter the clinic over the next year. Zhiyi operates two commercial-scale facilities and says the funds raised will be used to accelerate clinical development of its LBP product lines.
- Huaqin Communication Technology
Participated · Equity · Dec 2019
Huaqin Communication Technology is a China-based electronics production services provider and original design manufacturer that designs and produces communication and mobile devices. Founded in 2005, the company provides design and manufacturing services for mobile and communications equipment. The article reports Huaqin raised more than RMB1 billion (about $143m) in a financing round. That round valued the company at more than $2 billion. Investors named in the deal include Intel Capital, Qualcomm Ventures, Zhangjiang Hi-Tech, brokerage CMSC, CMB International and China Merchants Bank, as well as SinoKing Capital, Wise Road Capital and SummitView Capital. The article does not provide additional operating metrics or describe future plans. Huaqin Telecom is a Shanghai-based global original design manufacturer whose product lineup includes smartphones and tablets and extends to notebook computers, servers and Internet of Things devices. Led by President Vincent Qiu, the company serves global customers across multiple hardware categories. It received US$136M in a Series A financing to support its strategic initiatives. Huaqin plans to use the proceeds to develop its notebook computer and data center businesses, accelerate manufacturing automation and enhance vertical industry integration. Management says these moves are intended to bring added value to customers and expand its offerings beyond mobile devices. The company’s global footprint and product diversification position it to pursue growth across consumer and enterprise hardware segments.
Team
No current team members are available.